Wednesday, February 06, 2008
Bloomberg.com reports that Cytocore, Inc., has developped a new cervical cancer screening test that decreases the risk of false negatives.
SoftPAP, as the test is called, collects more cell specimens, making the likelihood of getting false tests results less likely.
The test also decreases women's chances of bleeding and spotting as a result of having a Pap smear. It is slated to be released onto the market later this year.
